LY6G6E

Across TCGA pan-cancer cohorts, LY6G6E RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated LY6G6E data layer compared with 1 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher LY6G6E RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LY6G6E expression acts as an unfavorable survival marker, although some lineages such as OV and ESCA show a favorable association.

ACC, LAML, and READ are the cancer types where LY6G6E RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Tertile	All	0.314	0.693	.001	75	view →
LAML	DFS	Tertile	All	0.205	0.586	.001	34	view →
READ	DFS	Median	IV	0.351	0.797	.001	29	view →
KICH	DFS	Tertile	All	0.521	0.969	.037	27	view →
OV	OS	Quartile	All	0.762	0.687	.006	26	view →
COAD	DFS	Quartile	All	0.589	0.871	<.001	24	view →
ESCA	OS	Tertile	II,III,IV	0.556	0.309	.013	18	view →
UCS	DFS	Tertile	IV	0.996	0.438	.024	16	view →
LUSC	OS	Tertile	II,III,IV	0.709	0.558	.019	16	view →
BLCA	DFS	Tertile	IV	0.207	0.490	.041	12	view →
HNSC	DFS	Median	All	0.638	0.462	.014	11	view →
STAD	DFS	Tertile	IV	0.144	0.444	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

LY6G6E–ACC (DFS)

Open the ACC breakdown →